vs
Side-by-side financial comparison of BankUnited, Inc. (BKU) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
BankUnited, Inc. is the larger business by last-quarter revenue ($288.2M vs $168.4M, roughly 1.7× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.2%).
BankUnited, Inc. is the bank holding company of BankUnited, N.A., a national bank founded in 1984 and headquartered in Miami Lakes, Florida. The company operates in Florida; the regions in and around Atlanta, Georgia; Dallas, Texas; Morristown, New Jersey; Charlotte, North Carolina; and in the New York metropolitan area. BankUnited also offers certain commercial lending and deposit products through national platforms and has total assets of $35.0 billion as of December 31, 2025
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BKU vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $288.2M | $168.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 31.2% | 50.6% |
| Net Margin | — | — |
| Revenue YoY | 9.0% | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.89 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $288.2M | $168.4M | ||
| Q3 25 | $275.7M | $87.3M | ||
| Q2 25 | $273.9M | $82.4M | ||
| Q1 25 | $255.4M | $65.0M | ||
| Q4 24 | $264.5M | $69.1M | ||
| Q3 24 | $257.0M | $51.6M | ||
| Q2 24 | $250.2M | $73.8M | ||
| Q1 24 | $241.7M | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | $71.9M | $-31.3M | ||
| Q2 25 | $68.8M | $-12.7M | ||
| Q1 25 | $58.5M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.5M | $-29.5M | ||
| Q2 24 | $53.7M | $-61.9M | ||
| Q1 24 | $48.0M | $61.0M |
| Q4 25 | 31.2% | 50.6% | ||
| Q3 25 | 35.5% | -11.4% | ||
| Q2 25 | 34.3% | 8.6% | ||
| Q1 25 | 31.4% | -34.0% | ||
| Q4 24 | 35.2% | -6.4% | ||
| Q3 24 | 32.4% | -31.0% | ||
| Q2 24 | 29.2% | 3.5% | ||
| Q1 24 | 27.8% | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | 26.1% | -35.9% | ||
| Q2 25 | 25.1% | -15.4% | ||
| Q1 25 | 22.9% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 23.9% | -57.2% | ||
| Q2 24 | 21.5% | -83.9% | ||
| Q1 24 | 19.8% | 44.3% |
| Q4 25 | $0.89 | $0.32 | ||
| Q3 25 | $0.95 | $-0.16 | ||
| Q2 25 | $0.91 | $-0.06 | ||
| Q1 25 | $0.78 | $-0.21 | ||
| Q4 24 | $0.91 | $-0.14 | ||
| Q3 24 | $0.81 | $-0.15 | ||
| Q2 24 | $0.72 | $-0.33 | ||
| Q1 24 | $0.64 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $217.8M | $167.9M |
| Total DebtLower is stronger | $319.7M | — |
| Stockholders' EquityBook value | $3.1B | $-302.0M |
| Total Assets | $35.0B | $465.9M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.8M | $167.9M | ||
| Q3 25 | $559.5M | $92.4M | ||
| Q2 25 | $801.3M | $86.1M | ||
| Q1 25 | $443.7M | $114.6M | ||
| Q4 24 | $491.1M | $144.8M | ||
| Q3 24 | $889.9M | $144.7M | ||
| Q2 24 | $433.5M | $189.3M | ||
| Q1 24 | $421.2M | $226.6M |
| Q4 25 | $319.7M | — | ||
| Q3 25 | $320.4M | — | ||
| Q2 25 | $708.9M | — | ||
| Q1 25 | $709.1M | — | ||
| Q4 24 | $708.6M | — | ||
| Q3 24 | $708.7M | — | ||
| Q2 24 | $708.8M | — | ||
| Q1 24 | $709.0M | — |
| Q4 25 | $3.1B | $-302.0M | ||
| Q3 25 | $3.0B | $-451.4M | ||
| Q2 25 | $3.0B | $-433.5M | ||
| Q1 25 | $2.9B | $-426.2M | ||
| Q4 24 | $2.8B | $-388.7M | ||
| Q3 24 | $2.8B | $-370.2M | ||
| Q2 24 | $2.7B | $-344.2M | ||
| Q1 24 | $2.6B | $-294.3M |
| Q4 25 | $35.0B | $465.9M | ||
| Q3 25 | $35.1B | $364.0M | ||
| Q2 25 | $35.5B | $347.1M | ||
| Q1 25 | $34.8B | $324.0M | ||
| Q4 24 | $35.2B | $343.8M | ||
| Q3 24 | $35.8B | $314.1M | ||
| Q2 24 | $35.4B | $352.3M | ||
| Q1 24 | $35.1B | $373.1M |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.26× | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $358.6M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $358.6M | $45.2M | ||
| Q3 25 | $99.7M | $-4.3M | ||
| Q2 25 | $117.6M | $-31.4M | ||
| Q1 25 | $16.4M | $-22.6M | ||
| Q4 24 | $433.8M | $-35.0M | ||
| Q3 24 | $46.1M | $-35.3M | ||
| Q2 24 | $135.7M | $-7.2M | ||
| Q1 24 | $66.5M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 2.53× | — | ||
| Q1 24 | 1.39× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BKU
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
